Skip to main content

Table 1 Endophthalmitis following intravitreal anti-VEGF injection—retrospective cases series with at least 10,000 injection

From: Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review

Period and location

Authors

n = injections

Rate of clinically suspected IE

Pre-injection antibiotics

Post injection antibiotics

Mask

Drape

Conjunctival povidone-iodine concentration

Anaesthetic agents used

Sterile lid speculum

Gloves

Location

1 Jan 2009 to 1 Oct 2012

Single-centre, USA

Storey et al. [16] (PIE study group)

Ophthal 2013

117,171

Overall

44/117,171 (0.038%; 1/2,663)

By Agent

Rani: 24/71,791 (0.033%; 1/2,991)

Bev: 20/44,007 (0.045%;1/2,200)

Aflib: 0/1,373

Variable

Variable

No*

No

5%

Drops

Subconj (rarely)

Variable

Nil*

Office

1 Jan 2005 to 31 Dec 2010

Single-centre (multi-site), USA

Moshfeghi et al. [17]

Retina 2011

60,322

Overall

12/60,322 (0.020%; 1/5,027)

By Agent

Rani: 5/18,607 (0.027%; 1/3,721)

Bev: 7/39,700 (0.018%; 1/5,671)

Peg: 0/2,015

No

Variable

No*

No

5%

Drops

Yes

Non-sterile

Office

1 Jan 2007 to 31 Dec 2011

Single-centre, USA

Chaudhary et al. [18]

Retina 2013

49,002

Overall

17/49,002 (0.035%; 1 in 2,882)

By Agent

Rani: 2/20,297 (0.0099%;1/10,149)

Bev: 15/28,705 (0.052%;1/1,914)

Yes

Yes

No

No

5%

Drops

Gel

Subconj

Yes

Nil or non-sterile

Office

2004 to 2012

Multicentre, Switzerland

Casparis et al. [19]

Retina 2014

40,011

Overall

3/40,011 (0.0075%;1 in 13,337)

By Agent

Rani: 3/36,398 (0.0082%, 1/12,133)

Bev: 0/3,518

Aflib:0/89

Peg: 0/6

No

Variable (yes in one hospital, no in the other)

Yes

Yes (adhesive)

5–10%

Drops

Yes

Sterile

OR

1 Aug 2006 to 31 Jul 2007

Multi-centre, USA

Klein et al. [20]

Ophthal 2009

30,736

Overall

15/30,736 (0.049%; 1/2,049)

By Agent

Rani: 10/22,579 (0.044%; 1/2,258)

Bev: 5/8,039 (0.062%; 1/1,608)

Peg: 0/128

Variable

?

?

?

5–10%

?

Variable: used in 14 of the 15 cases with endophthalmitis

?

Office

July 2000 to July 2010

Single-centre (multi-site), USA

Chen et al. [21]

Retina 2011

29,995

Overall

11/29,995 (0.037%; 1/2,727)

By Agent

Rani: 8/22,336 (0.036%; 1/2,792)

Bev: 3/6,675 (0.045%; 1/2,225)

Peg: 0/984

Yes

Yes

No*

No*

5–10%

Drops

Gel

Subconj

Yes

Non-sterile*

Office

1 Jun 2005 to 7 Aug 2007

Multicentre, USA

Fintak et al. [22]

Retina 2008

26,905

Overall

6/26,905 (0.022%; 1/4,484)

By Agent

Rani: 3/14,320 (0.021%; 1/4,773)

Bev: 3/12,585 (0.024%; 1/4,195)

No*

Variable (used in all the cases of endophthalmitis)

No*

No*

5–10%

Drops

Gel

Subconj

Variable (used in all the cases of endophthalmitis)

Fingers to spread the eyelids in a minority

Nil*

Office

March 2007 to May 2013

Single-centre, Denmark

Brynskov et al. [23]

Retina 2014

20,293

Overall

0/20,293

By Agent

Rani: 0/20,024

Aflib: 0/269

No

Variable

Yes

Yes (adhesive)

5%

Drops

Yes

Sterile

OR

1 Aug 1997 to

31 Oct 2012

Single-centre, USA

Bhavsar and Sandler [24]

Retina 2015

17,666

Overall

1/17,666 (0.0057%, 1/17,666)

By Agent

Rani: 0/1,669

Bev: 1/15,479 (0.0065%, 1/15,479)

Aflib: 0/148

Peg: 0/370

No

No

No

No

5% (before and after injection)

Drops

Yes

Non-sterile

Office

Jan 2005 to end July 2012

Single-centre, Germany

Nentwich et al. [25]

Retina 2014

18,202

Overall

3/18,202 (0.016%; 1/6,067)

By Agent

Rani: 1/10,097 (0.010%, 1/10,097)

Bev: 2/7,865 (0.025%;1/3,932)

Peg: 0/240

No

Yes

Yes

Yes (non-adhesive)*

1%

Drops

Yes

Sterile

OR

Jan 2007 to May 2012

Multicentre, India

Mithal et al. [26]

BJO 2013

15,925

Overall

8/15,925 (0.050%;1/1,991)

By Agent

Rani: 1/705

(0.14%; 1/705)

Bev: 7/15,035 (0.044%;1/2,275)

Peg: 0/185

No*

Yes*

Yes*

Variable

2.5%*

Drops*

Yes*

Sterile*

Office*

July 2009 to July 2012

Single-centre, Japan

Shimada et al. [27]

Graefes 2013

15,144

Overall

0/15,144

By Agent

Rani: 0/13,750

Bev: 0/846

Peg: 0/548

Yes

Yes

Yes

Yes (adhesive)

0.25% (before and after injection)

Drops + Subconj

Yes

Yes

Office

Jan 2005 to Aug 2010

Multi-centre, Canada

Cheung et al. [28]

Ophthal 2012

14,960

Overall

7/14,960 (0.047%; 1/2,137)

By Agent

Rani: 3/9,453 (0.032%; 1/3,151)

Bev: 4/5,386 (0.074%; 1/1,347).

Peg: 0/121

Variable

Variable

No*

No

10%

Drops

Gel

Yes

Nil*

Office

Mar 2006 to Mar 2012

Multi-centre (single-surgeon), Australia

Abell et al. [29]

BJO 2012

12,249

Overall

4/12,249 (0.033%; 1/3,062)

By Agent

Rani: 3/10,574 (0.028%; 1/3,525)*

Bev: 1/1,675 (0.060%; 1/1,675)*

No

Variable (used until 2011)*

Yes

Yes (non-adhesive)*

10%

Drops + Gel*

Yes

Sterile

Office = 4/3,376

OR = 0/8,873

Jan 2009 to Dec 2011

Multi-centre, USA and Italy

Tabandeh et al. [30]

Retina 2014

11,257

Overall

5/11,257

By Agent

Rani: 3/2,724 (0.11%; 1/908)

Bev: 2/8,533 (0.023%; 1/4,267)

Yes in OR

No in office

Yes

Yes in OR

No in office

Yes in OR

No in office

5%

Drops

Subconj

Yes

Sterile in OR

Non-sterile in office

Office = 3/8,647

OR = 2/3,063

5 Jan 2005 to 18 Oct 2007

Single-centre (multi-site), USA

Pilli et al. [31]

AJO 2008

10,254

Overall

2/10,254 (0.020%; 1/5,127)

By Agent

Rani: 1/6,347

(0.016%; 1/6,347)

Bev: 1/3,501 (0.029%; 1/3,501)

Peg: 0/406

No

Yes

No

No

5%

Drops

Variable

? “Surgical attire was not used”

Office

Nov 2010 to Dec 2011

Single-centre, USA

Fineman et al. [32]

Retina 2013

10,164

Overall

3/10,164

(0.030%; 1/3,388)

By Agent

Rani: 1/6,330 (0.016%;1/6,330)

Bev: 2/3,834 (0.052%; 1/1,917)

No*

Variable (used until Oct 2,011)

No*

No*

5%

Drops

No

Nil or non-sterile*

Office*

1 Jan 2007 to 31 Dec 2011

Single-centre, USA

Englander et al. [33]

BJO 2013

10,140

Overall

3/10,140 (0.030%, 1/3,380)

By Agent

Rani: 3/7,768 (0.039%; 1/2,589)

Bev: 0/2,315

Peg: 0/57

Variable*

Variable

Variable*

Variable

Yes, 5%

Drops

Subconj.

Variable

Variable*

Office*

  1. Steroid and other injections have been excluded.
  2. Anesthetic: “Drops” refers to drops given alone or with the aid of a cotton bud or pledget.
  3. Location: “office-based” includes studies where the injections were performed in a clean procedure room, or in the consulting room itself, within an office or outpatients department.
  4. Rani ranibizumab, Bev bevacizumab, Aflib aflibercept and Peg pegaptanib.
  5. * These points were not explicitly mentioned in the manuscript, but were clarified through personal communication with the corresponding author of the paper.
  6. ? These points were not mentioned in the manuscript, and the corresponding authors could not be contacted.